TMX Newsfile Psychedelics News Releases

Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program

Thu, 03 Sep 2026 07:39:00 -0400

Filament Health has completed a further international delivery of its patented, naturally derived psilocybin drug candidate PEX010 to Germany, supporting the first compassionate use program for psilocybin in the European UnionThe Company believes the continued delivery demonstrates Filament's ability to manufacture, release and supply pharmaceutical-grade botanical psilocybin across international regulatory jurisdictions as new legal access pathways emergeRhelion intends to leverage Filament's...

Numinus Wellness Inc. Provides Corporate Update

Tue, 01 Sep 2026 05:39:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Numinus Wellness Inc. (OTC Pink: NUMIF) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced that it has filed all quarterly interim financial reports for fiscal year 2026 to May 31, 2026.With the recent completion of the August 31, 2025, audit, together with the filings of the Company's...

Rhelion Life Sciences Reports First Quarter 2027 Results

Mon, 31 Aug 2026 08:39:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to report its financial and operational results for the three months ended June 30, 2026 ("Q1 2027"), capping a transitional quarter which culminated in the acquisition of Filament Health Corp. ("Filament"). All figures are reported in...

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Fri, 28 Aug 2026 17:00:00 -0400

Q4 Fiscal 2025 HighlightsRevenue of $2.3 million, a 29.0% increase over Q3 2025Gross profit of $1.4 million, compared to a gross profit of $0.8 million in Q3 2025Cash position of $0.5 million as of August 31, 2025Subsequent to Quarter EndOn April 18, 2026, President Donald Trump signed an executive order directing U.S. federal agencies to accelerate research, access, and regulatory review for psychedelic-based treatments, including psilocybin, ibogaine, MDMA, and LSD, and committing US$50...

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate

Thu, 27 Aug 2026 08:24:00 -0400

A new United States patent, "Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids," issued this month, adding to the intellectual property estate behind PEX010, the standardized natural psilocybin drug candidate supporting more than 80 studies worldwide.Toronto, Ontario--(Newsfile Corp. - August 27, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research...

Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression

Tue, 25 Aug 2026 07:20:00 -0400

Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy in people living with metastatic solid tumors or incurable hematologic malignancies.Toronto, Ontario--(Newsfile Corp. - August 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within...

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design

Thu, 20 Aug 2026 07:39:00 -0400

Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee® imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnestic mild cognitive impairment, as well as Darmiyan's core technology, the Virtual Microscope, tailored towards use in pharmaceutical clinical trialsThe goal of the collaboration is to inform the identification, selection and monitoring of the best candidates for clinical trials of PEX010, Rhelion's...

Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO

Wed, 19 Aug 2026 08:14:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce the appointment of Samiuddin Khaja as Chief Financial Officer ("CFO") effective immediately.The appointment comes as Rhelion continues its evolution into a focused, research-led life sciences company following the acquisition...

Adaptogenics Health Corp. Announces Non-Brokered Private Placement

Fri, 14 Aug 2026 18:56:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 14, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") is pleased to announce it is launching a non-brokered private placement of up to 4,000,000 common shares (the "Shares"), at a price of $0.08 per Share for gross proceeds of up to $320,000 (the "Offering"). The Company will use the net proceeds from the Offering for general working capital.The Company may elect to close the Offering in one or more tranches. It is...

Hanf.com Transaction Advances as Neural Therapeutics Receives CSE Conditional Approval

Fri, 14 Aug 2026 17:01:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of the Company's shares following completion of its previously announced fundamental change transaction involving CWE European Holdings Inc. ("CWE"), which operates the Hanf.com business in Germany (the "Series B Transactions"). Upon...